secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000875045-24-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q2 revenue flat at $2.47B; Non-GAAP EPS up 31% to $5.28; raises FY2024 guidance
--------------------------------------------------------------------------------

- Q2 total revenue $2,465M flat YoY; GAAP diluted EPS $4.00 (-2%), Non-GAAP diluted EPS $5.28 (+31%).
- Core pharma revenue up 5% actual/6% CC; LEQEMBI global in-market sales ~$40M (US ~$30M).
- SKYCLARYS rev $100M, ZURZUVAE rev $15M; completed HI-Bio acquisition expanding immunology pipeline.
- Raised FY2024 Non-GAAP EPS guidance to $15.75-$16.25 (mid-point ~9% growth vs FY2023).
- Retains Biosimilars business; expects operating income growth mid- to high-teen % and margin improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504524000022/0000875045-24-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504524000022/biib-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000875045-24-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer